Government Investigation Finds Flaws In the FDA鈥檚 Orphan Drug Program
A probe by the Government Accountability Office cites breakdowns in the Food and Drug Administration program that approves drugs for rare diseases.
Drug Costs
441 - 460 of 698 Results
-
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 Reading The Tea Leaves In Blue Wave鈥檚 Wake
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Mary Agnes Carey of Kaiser Health News, Margot Sanger-Katz of The New York Times, Alice Ollstein of Politico and Anna Edney of Bloomberg News discuss the impact of House Democratic leadership elections and their impact on health policy; as well as efforts by the Trump administration to address high drug prices and ensure the safety of medical devices. Plus, Julie Rovner interviews KHN鈥檚 Jay Hancock about the latest 鈥淏ill of the Month.鈥
-
Democrats Winning Key Leadership Jobs Have Taken Millions From Pharma
Top House Republican also received more than $1 million from drugmakers since 2007.
-
Fish Oil Drug Looks Heart-Healthy. Just Don鈥檛 Swallow It Hook, Line And Sinker.
The complete findings of a recent study show the FDA-approved drug Vascepa reduced the likelihood of cardiovascular death, stroke and other heart conditions in some patients. But science didn鈥檛 find the same promise for over-the-counter fish oil supplements when tested in healthy people.
-
New Congress To Tackle Burning Health Care Issues, Including Drug Prices
KHN鈥檚 Sarah Jane Tribble discusses the twists and turns with CBS News.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 Doctors, Guns And Lame Ducks
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Kimberly Leonard of the Washington Examiner and Alice Ollstein of Politico discuss how the Democrats鈥 takeover of the House and other results from the Nov. 6 elections might affect health care, and what Congress may have in store for the lame-duck session.
-
House Dems In New Seats Of Power Will Steer Health Policy, Attack Drug Prices
Democrats, who have a history of championing the Affordable Care Act and railing about drug prices, will now chair several house committees.
-
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 Open Enrollment And A Midterm Preview
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Joanne Kenen of Politico discuss the start of open enrollment for individual health insurance plans for 2019 and preview what next week鈥檚 midterm elections might mean for health policy. Plus, Barbara Feder Ostrov of KHN and California Healthline talks to Julie about the latest NPR-KHN 鈥淏ill of the Month鈥 feature.
-
Pricey Precision Medicine Often Financially Toxic For Cancer Patients
Medical treatments targeting the DNA in tumor cells are celebrated, but insurers often won鈥檛 cover the skyrocketing cost.
By Liz Szabo -
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Trump Adds A Global Pricing Plan To Wide Attack On Drug Prices, But Doubts Persist
Over the past five months, the Trump administration has proposed a series of reforms to lower the cost of prescription drugs.
-
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 Trump, GOP Fight Back On Health Care
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Kimberly Leonard of the Washington Examiner and Alice Ollstein of Politico discuss a flurry of proposals from the Trump administration on prices Medicare pays for drugs and the Affordable Care Act.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 Republicans鈥 Preexisting Political Problem
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Stephanie Armour of The Wall Street Journal and Joanne Kenen of Politico discuss how protections for people with preexisting conditions have become a top issue in the elections, Trump administration efforts to make prescription drug prices more public and the start of Medicare鈥檚 annual open-enrollment period. Plus, Rovner interviews California Attorney General Xavier Becerra.
-
TV Ads Must Trumpet Drug Prices, Trump Administration Says. Pharma Tries A Plan B.
Drug pricing is a top issue in the run-up to the midterm elections.
By Shefali Luthra and Sarah Jane Tribble -
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 Falling Premiums And Rising Political Tensions
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Mary Agnes Carey of Kaiser Health News, Rebecca Adams of CQ Roll Call, Anna Edney of Bloomberg News and Julie Appleby of Kaiser Health News discuss the Trump administration鈥檚 announcement that average premium prices are falling on the Obamacare marketplaces, the effort by Senate Democrats to reverse rules on short-term health insurance and the focus on protections for people with preexisting conditions in the run-up to midterm elections.
-
No More Secrets: Congress Bans Pharmacist 鈥楪ag Orders鈥 On Drug Prices
Congress approved two bills last month that prohibit provisions keeping pharmacists from telling patients when they can save money by paying the cash price instead of the price negotiated by their insurance plan.
By Susan Jaffe